Please login to the form below

Not currently logged in
Email:
Password:

Vimizim

This page shows the latest Vimizim news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

them.”. Another variant of the disease, MPS IVa already has a treatment available – Biomarin’s Vimizim.

Latest news

  • BioMarin's real world data sways NICE on orphan drug Vimizim BioMarin's real world data sways NICE on orphan drug Vimizim

    Rare genetic disorder treatment recommended in final draft guidance. NICE has issued final draft guidance recommending BioMarin Pharma's Vimizim (elosulfase alfa) for the treatment of the rare genetic disorder Morquio ... real world data for Vimizim,

  • BioMarin drug boosts growth in children with dwarfism BioMarin drug boosts growth in children with dwarfism

    BioMarin is a rare disease specialist and already sells several products including Vimizim (elosulfase alfa) for mucopolysaccharidosis (MPS) type IVA and Naglazyme (galsulfase) for MPS type VI.

  • Sanofi and Regeneron pay $67.5m to speed alirocumab review Sanofi and Regeneron pay $67.5m to speed alirocumab review

    California-based BioMarin was awarded the voucher in February, when it received approval for Vimizim, a new biological product for patients with the rare disease Mucopolysaccharidosis type IVA, also known as

  • EC approves Biomarin rare genetic disorder drug EC approves Biomarin rare genetic disorder drug

    Vimizim now available to treat Morquio A syndrome. BioMarin has won EU approval to market its drug Vimizim for the rare genetic disorder Morquio A syndrome. ... Vimizim (elosulfase alfa) works by replacing this missing enzyme, and has demonstrated an

  • FDA backs BioMarin drug for rare enzyme disorder FDA backs BioMarin drug for rare enzyme disorder

    Vimizim is first drug approved in US under rare paediatric disease priority review. ... Marketing applications for Vimizim are also currently under review in the EU, Brazil, Australia, Canada and Mexico. .

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    Sales of the product will fit well into BioMarin's commercial infrastructure for its enzyme replacement therapies Naglazyme (galsulfase), for the treatment of Mucopolysaccharidosis VI, and Vimizim (elosulfase alfa) for Morquio

  • Pharma deals during November 2014 Pharma deals during November 2014

    BioMarin was awarded a Rare Pediatric Disease PRV when it received approval of Vimizim, a new biological product for patients with Mucopolysaccharidosis type IVA.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Nektar Therapeutics appoints Jeff Ajer Nektar Therapeutics appoints Jeff Ajer

    officer. There he worked on establishing BioMarin’s global footprint and commercial infrastructure and has played a leadership role in the launches and growth strategies for brands including Brineura, Vimizim, Kuvan

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics